Universität zu Köln

Zittermann, A., Ernst, J. B., Prokop, S., Fuchs, U., Dreier, J., Kuhn, J., Berthold, H. K., Pilz, S., Gouni-Berthold, I. and Gummert, J. F. (2018). Vitamin D supplementation and bone turnover in advanced heart failure: the EVITA trial. Osteoporosis Int., 29 (3). S. 579 - 587. LONDON: SPRINGER LONDON LTD. ISSN 1433-2965

Full text not available from this repository.

Abstract

Low vitamin D status is common in patients with heart failure and may influence bone health. A daily vitamin D dose of 4000 IU (moderately high dose) for 3 years had however no effect on parameters of bone metabolism, even in patients with very low vitamin D status. Introduction Low vitamin D status is common in patients with heart failure (HF) and has been related to disturbed bone turnover. The present study investigated the effect of a daily vitamin D-3 dose of 4000 IU on bone turnover markers (BTMs) in patients with advanced HF and 25-hydroxyvitamin D (25OHD) concentrations < 75 nmol/L. Methods In this pre-specified secondary analysis of a randomized controlled trial, we assessed in 158 male HF patients (vitamin Dgroup: n = 80; placebo group: n = 78) between-group differences in calciotropic hormones (25OHD, 1,25-dihydroxyvitamin D [1,25(OH) 2D], intact parathyroid hormone [iPTH]), and BTMs (cross-linked C-telopeptide of type I collagen, bone-specific alkaline phosphatase, undercarboxylated osteocalcin). Comparisons were performed at the end of a 3-year vitamin D supplementation period with adjustments for baseline values. Results Compared with placebo, vitamin D increased 25OHD on average by 54.3 nmol/L. At study termination, 25OHD and 1,25(OH) 2D were significantly higher (P < 0.001 and P = 0.007, respectively), whereas iPTH tended to be lower in the vitamin D group than in the placebo group (P = 0.083). BTMs were initially within their reference ranges and did not differ significantly between groups at study termination, neither in the entire study cohort nor when data analysis was restricted to the subgroup of patients with initial 25OHD concentrations < 30 nmol/L (n = 54) or to patients with initial hyperparathyroidism (n = 65) (all P values > 0.05). Conclusions Adaily vitamin D-3 dose of 4000 IU did not influence BTMs. Data indicate that vitamin D supplementation will not lower bone turnover in male patients with heart failure.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Zittermann, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ernst, J. B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Prokop, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuchs, U. UNSPECIFIED UNSPECIFIED UNSPECIFIED Dreier, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kuhn, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Berthold, H. K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pilz, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gouni-Berthold, I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gummert, J. F. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-194742
DOI:	10.1007/s00198-017-4312-9
Journal or Publication Title:	Osteoporosis Int.
Volume:	29
Number:	3
Page Range:	S. 579 - 587
Date:	2018
Publisher:	SPRINGER LONDON LTD
Place of Publication:	LONDON
ISSN:	1433-2965
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language RANDOMIZED CONTROLLED-TRIAL; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; 25-HYDROXYVITAMIN D; UNDERCARBOXYLATED OSTEOCALCIN; CARDIAC TRANSPLANTATION; FRACTURE RISK; YOUNG-WOMEN; CALCIUM Multiple languages Endocrinology & Metabolism Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/19474